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Discovering Modes of Action
for Therapeutic Compounds Using
a Genome-Wide Screen of Yeast Heterozygotes
analyzing the modes of action of clinically relevant
compounds.
Introduction
Pek Yee Lum,1,6,* Christopher D. Armour,1,6
Sergey B. Stepaniants,1 Guy Cavet,1
Maria K. Wolf,3 J. Scott Butler,3 Jerald C. Hinshaw,5
Philippe Garnier,5 Glenn D. Prestwich,5
Amy Leonardson,1 Philip Garrett-Engele,1
Christopher M. Rush,4 Martin Bard,4 The sequencing of the human genome has revealed
Greg Schimmack,1 John W. Phillips,2 thousands of putative proteins that have the potential
Christopher J. Roberts,1 and Daniel D. Shoemaker1 to revolutionize modern medicine (Lander et al., 2001).
1Rosetta Inpharmatics LLC, a wholly-owned A critical step in translating genomic information into
subsidiary of Merck & Co., Inc. new therapeutics will be to develop approaches that
12040 115th Avenue N.E. can rapidly distinguish high-quality drug targets among
Kirkland, Washington 98034 the thousands of potential candidates. Identifying the
2 Merck & Co., Inc. cellular targets of clinically proven small molecules is a
126 East Lincoln Avenue powerful approach to identify proteins that can be safely
R80Y-255 and effectively targeted in humans. Interestingly, many
Rahway, New Jersey 07065 of the therapeutic compounds on the market today were
3 Department of Microbiology and Immunology discovered fortuitously with no a priori knowledge of
J.P. Wilmot Cancer Center the target or mechanism of action. For example, the
University of Rochester School of Medicine and beneficial effects of niacin on lipid levels in humans have
Dentistry been known since 1955, while identification of its cellular
601 Elmwood Avenue target remained elusive until just recently (Knopp, 1999;
Rochester, New York 14642 Tunaru et al., 2003). The importance of the identification
4 Department of Biology of the target of a clinically proven molecule such as
Indiana University-Purdue University Indianapolis niacin shows that these molecules provide a rich source
723 West Michigan Street of chemical probes that can be used to mine the human
Indianapolis, Indiana 46202 genome for the next generation of high-quality drug
5 Department of Medicinal Chemistry targets.
The University of Utah A major challenge facing this type of approach is the
419 Wakara Way, Suite 205 need for new tools that can rapidly identify the protein
Salt Lake City, Utah 84108 targets of small molecules with interesting biological
properties. The emergence of new technologies such as
protein arrays (MacBeath and Schreiber, 2000; Service,
2000), reverse transfection (Phizicky et al., 2003; Ziaud-Summary
din and Sabatini, 2001), and DNA microarrays (Huels et
al., 2002) has accelerated this type of discovery effort.Modern medicine faces the challenge of developing
Model organisms such as Saccharomyces cerevisiaesafer and more effective therapies to treat human dis-
have also proven to be powerful tools for mechanisticeases. Many drugs currently in use were discovered
studies of clinically relevant compounds (Heitman etwithout knowledge of their underlying molecular
al., 1991; Schreiber and Crabtree, 1992), which is mademechanisms. Understanding their biological targets
possible by the fact that many human disease-associ-and modes of action will be essential to design im-
ated genes have highly conserved yeast counterpartsproved second-generation compounds. Here, we
(Foury, 1997; Steinmetz et al., 2002).describe the use of a genome-wide pool of tagged
A study by Giaever et al. (1999) demonstrated thatheterozygotes to assess the cellular effects of 78 com-
parallel analysis of yeast strains with heterozygous dele-pounds in Saccharomyces cerevisiae. Specifically, la-
tions of drug target genes can be used to monitor com-nosterol synthase in the sterol biosynthetic pathway
pound activities in vivo. Specifically, they showed thatwas identified as a target of the antianginal drug molsi-
reducing the gene copy number of drug targets in adomine, which may explain its cholesterol-lowering
diploid cell can result in sensitization to the drug ofeffects. Further, the rRNA processing exosome was
interest. We have extended this approach to analyzeidentified as a potential target of the cell growth inhibi-
the activities of 78 chemical entities, most of which aretor 5-fluorouracil. This genome-wide screen validated
medically relevant. In addition, we increased the numberpreviously characterized targets or helped identify po-
of mutant strains to represent over half of the yeasttentially new modes of action for over half of the com-
genome and used high-density oligonucleotide arrayspounds tested, providing proof of this principle for
with a two-color labeling strategy to monitor growth
rates. Finally, a strain-specific error model was used to
identify drug-dependent fitness defects that are statisti-*Correspondence: pek_lum@merck.com; shoemakd@stanford.
cally significant. In this study, we correctly identified thealumni.org
6 These authors contributed equally to this work reported targets for many well-characterized com-
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Figure 1. Schematic Representation of the Fitness Profiling Experimental Strategy
(A) Growth of tagged heterozygous deletion pool grown in the presence of drug.
(B) Isolation of genomic DNA from cultures before (G-0) and after (G-20) outgrowth.
(C) Amplification and labeling of barcode tags by PCR.
(D) Hybridization of labeled barcode tags to DNA microarrays. Signal intensities resulting from microarray hybridizations are proportional to
the relative tag abundances in the pool population. The inset shows an enlargement of a microarray following hybridization with examples of
an enriched strain (red spot), a depleted strain (green spot), and a strain that was unchanged (yellow spot).
pounds in addition to discovering many potentially novel cedures). Competitive growth of the mutant pool was
carried out for 20 generations in media containing se-drug targets.
lected compounds (Figure 1A). Strain abundance was
measured before and after outgrowth by hybridizationResults
of differentially labeled (Cy3/Cy5) barcode tags to DNA
microarrays (Figures 1B–1D). Deletion strains that wereStudy Design Rationale
The experimental strategy used to interrogate drug ac- sensitive to a given compound were outcompeted by
thousands of unaffected strains in the pool. Compoundstivities in this study is outlined in Figure 1. A mixture of
isogenic yeast mutants was generated by pooling 3503 were administered at concentrations resulting in moder-
ate growth inhibition to ensure that the activities of theheterozygous deletion strains engineered with strain-
specific molecular barcode tags (see Experimental Pro- putative drug target(s) were rate limiting for growth. Un-
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Figure 2. Identification of Drug-Specific
Growth Defects
(A) Compilation of signal intensity data for the
ERG1 heterozygote barcode tag across all 78
drug treatments. The Cy3 (green) or Cy5 (red)
signal intensities were obtained from tag-
specific oligonucleotide features represented
in triplicate on the microarray. In most drug
treatments, the Cy3 and Cy5 intensities were
roughly equal indicating that the strain abun-
dance remained unchanged over the course
of most drug treatments. In the terbinafine
treatment, however, the Cy5 intensity is much
lower than that of the Cy3 for the ERG1 het-
erozygote tag. This indicates that the relative
abundance of the ERG1 heterozygote was
depleted during outgrowth in the presence of
terbinafine, which is known to inhibit Erg1p
activity.
(B) Statistical significance of terbinafine-spe-
cific fitness changes in the pool. Hybridiza-
tion data across all drug treatments were
used to determine the average performance
of each strain during outgrowth. A modified
Student’s t test was used to calculate confi-
dence levels by comparing the fitness levels
from individual treatments to the average per-
formance across all treatments. The resulting
P values for each strain in the terbinafine
treatment are plotted on the x axis and the
number of strains with a given P value are
plotted on the y axis. Notice that the erg1/
ERG1 strain is the single outlier in the terbi-
nafine treatment.
der these conditions, strains that are heterozygous for ments as indicated by the similarity of hybridization in-
tensities before and after each of the competitive growthdrug target genes have the greatest chance of displaying
hypersensitivity phenotypes (Giaever et al., 1999). experiments. However, the log10 intensities of the ampli-
fied tags showed a significant reduction following treat-
ment with terbinafine suggesting that the erg1/ERG1Identifying Drug-Specific Growth Defects
strain had been depleted from the population. FigureA strain-specific error model was developed to distin-
2B shows the results of log10 P values for all 3503 strainsguish between general and drug-dependent growth de-
in the pool following terbinafine treatment. The ERG1fects. To accomplish this, a reference set was generated
heterozygote was the most significant outlier with a Pby calculating the mean performance of each strain
value of less than 1  1085.across a large number of competitive growth experi-
ments. Next, the scatter error for these measurements
was calculated to determine the reproducibility of each Large-Scale Analysis of 78 Compounds
This screen was initiated by testing commercially avail-strain’s performance. To identify strains with drug-spe-
cific changes in growth rates, the fitness values from a able compounds for the ability to inhibit growth in our
yeast strain background (see Experimental Proceduresgiven drug treatment were compared to the correspond-
ing values in the reference set using a modified Stu- for description). Seventy-eight compounds that induced
moderate levels of growth inhibition (0.70  pooldent’s t test (see Experimental Procedures). The re-
sulting P values reflect the probability that the observed fitness  0.96; see Experimental Procedures for defini-
tion of pool fitness) were selected for analysis (Table 1).growth rate in any given drug treatment could occur by
chance based on the strain’s behavior in the refer- The compounds analyzed in this study included many
clinically used therapeutic agents and agriculturalence set.
Figure 2A shows an example of the hybridization data chemicals. Figure 3 shows an overview of the P value
data for all 3503 strains across the 78 compound treat-collected for one of the heterozygotes (ERG1) before
(Cy3) and after (Cy5) each of the 78 different competitive ments (also in Supplemental Table S1 available at http://
www.cell.com/cgi/content/full/116/1/121/DC1). Of thegrowth experiments. The 20 bp tags for each of the
strains in the pool were printed in triplicate on the mi- 78 compounds analyzed, 18 resulted in no drug-specific
fitness changes (Group I), 56 resulted in a small numbercroarrays that were used for these experiments. In this
example, the relative growth rate of the ERG1 heterozy- of significant outliers (Group II), and 4 resulted in wide-
spread fitness changes (Group III) compared to the refer-gote was not affected by the majority of the drug treat-
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Figure 3. Comprehensive View of Fitness Profiles for 78 Compounds
Dot plots were calculated by comparing drug-specific growth rates of each heterozygous deletion strain to its average behavior from the
reference set. Statistical significance was determined for each strain’s fitness value and the resulting P values were plotted for strains with
drug-specific growth deficits. Each data point represents one heterozygous deletion strain with a growth deficit. The confidence level of each
strain’s growth rate is plotted along the x axis as the log10 P value. The P value distributions are most useful for identifying outlier strains
within drug treatments. Compounds are sorted by the overall distribution of the heterozygous deletion pool with compounds causing relatively
few fitness changes at the top and those causing widespread fitness changes at the bottom. Group I includes compounds with no drug-
specific fitness changes. Compounds in Group II resulted in a small number of highly significant outliers. Group III compounds induced
widespread fitness changes in the pool.
ence set. Hypersensitive heterozygotes resulting from Fitness Profiling Identifies Known Activities
of Well-Characterized Compoundsthe compound treatments in Group II represent the most
attractive candidates for further analysis due to the rela- To determine the sensitivity of this method, we analyzed
the results for 20 compounds with reported protein tar-tively small number of highly significant outliers.
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Figure 4. High Resolution View of Selected Fitness Profiles from Group II Compounds
(A) Compounds with previously reported protein targets in yeast.
(B) Selected compounds with no reported protein targets in yeast.
In Figures 4A and 4B, the three most significant outliers are listed on the right side of each P value plot and the x axis has been specifically
scaled to the P value distribution of each drug treatment. Outliers are listed from left to right in order of decreasing log10 P values.
gets in yeast (Table 1). The correct targets or constit- ergosterol pathway. These included lovastatin (HMG1)
(Rine et al., 1983), terbinafine (ERG1) (Jandrositz et al.,uents of target complexes were identified for the major-
ity of these well-characterized compounds (Figure 4A). 1991), clotrimazole (ERG11) (Truan et al., 1994), fenpro-
pimorph (ERG2) (Marcireau et al., 1990), and dyclonineSix of the correctly identified targets involved com-
pounds that inhibit distinct biochemical steps along the (ERG2) (Hughes et al., 2000). Haloperidol affected ERG3
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and ERG24 heterozygotes, which are adjacent to the Inhibition of Lanosterol Synthase (Erg7p)
proposed target (ERG2) in the pathway (Moebius et al., by Molsidomine
1996). In addition, we found that three different sulfa- Molsidomine (N-ethoxycarbonyl-3-morpholino-sydnon-
based drugs (asulam, sulfamethoxazole, and sulfanil- imine) is a potent vasodilator used clinically to treat
amide) affected folic acid biosynthesis as reported in angina for the past twenty years. Enzymatic modification
the literature (Nardese et al., 1996; Patel et al., 2003). of molsidomine in the human liver results in derivatives
Although broad-spectrum lethality resulted from treat- (Figure 5A) that are effective nitric oxide donors, an
ment with carbendazim, a benomyl-analog known to activity that accounts for the vasodilatory properties
target tubulin, the most affected strains were heterozy- observed in mammals (Reden, 1990). Fitness profiling
gotes of genes involved in microtubule formation (GIM2 revealed significant molsidomine-induced haploinsuffi-
and GIM3) (Geissler et al., 1998; Neff et al., 1983). The ciency for only the ERG7 (lanosterol synthase) heter-
targets were also correctly identified for compounds ozygote (Figure 5B). Lanosterol synthase is a highly
that inhibit the small unit of ribonucleotide reductase conserved and essential component of ergosterol bio-
(hydroxyurea) (Rittberg and Wright, 1989); the 60s ribo- synthesis (Corey et al., 1994; Lees et al., 1995). This
somal subunit (cycloheximide) (Stocklein and Piepers- finding was further supported by the observation that
berg, 1980); the protein kinase C complex (stauro- overexpression of ERG7 in a wild-type yeast strain con-
sporine) (Yoshida et al., 1992); and protein glycosylation fers resistance to molsidomine (Figure 5C) and that mol-
(tunicamycin) (Barnes et al., 1984). These examples sidomine causes an accumulation of the Erg7p sub-
demonstrate that fitness profiling can accurately detect strate, 2,3-oxidosqualene (data not shown), as is
the cellular effects of drugs in a variety of biochemical observed with other Erg7p inhibitors and in an erg7
pathways. deletion strain (Milla et al., 2002). All of these data are
Some compounds with known yeast targets yielded indicative of Erg7p inhibition.
unexpected results. Treatment with methotrexate, for Next, we asked whether molsidomine could block the
example, resulted in identification of CIN1 but not the activity of lanosterol synthase from other organisms.
gene (DFR1) encoding the known target dihydrofolate Specifically, we measured the effect of molsidomine and
reductase (Huang et al., 1992). Given the nonessential its metabolites on mammalian and bacterial homologs
role of Cin1p in microtubule formation, it is likely that of ERG7. We found that lanosterol synthase purified
the observed drug sensitivity resulted from a synthetic from rat liver (Abe and Prestwich, 1995) was potently
lethal interaction with the known target. In another ex- inhibited in vitro by SIN-1, the first metabolic derivative
ample, camptothecin unexpectedly induced a growth of molsidomine (Figure 5D). Likewise, in vitro inhibition
defect in the trx2/TRX2 strain, while the heterozygote of recombinant lanosterol synthase from Alicyclobacil-
of the known target gene (TOP1) was unaffected (Pom- lus acidocaldarius (Ochs et al., 1992) was observed for
mier et al., 1998). Identification of TRX2, a nonessential SIN-1 (Figure 5E). Together these results indicate that
gene involved in the tolerance of oxidative stress, is molsidomine effectively blocks sterol synthesis through
supported by a recent report in plants showing that the inhibitory effect of its metabolite SIN-1 on lanosterol
camptothecin induces oxidative stress via the mito- synthase. Interestingly, previous reports have shown
chondrial respiratory chain (Weir et al., 2003). The het- that molsidomine lowers cholesterol levels in both rats
erozygote for PMA1, which encodes the H-ATPase tar- and humans (Chassoux, 1989; Granzer and Ostrowski,
geted by omeprazole (Monk et al., 1995), was not 1984). As the metabolism of molsidomine in humans
affected by drug treatment. This may be due to comple- and rats is quite similar, providing SIN-1 as an active
mentation of the drug-induced inhibition of Pma1p by intermediate (Tanayama et al., 1974; Wilson et al., 1987),
the functionally overlapping PMA2 protein. Finally, three the results from this study identify the likely molecular
compounds (5-fluorocytosine, 5-fluorouracil, and FUDR) mechanism for the cholesterol lowering properties of
known to inhibit Cdc21p induced growth defects in
this drug.
members of the rRNA processing complex in addition
to the expected target (CDC21 was one of the top 10
Disruption of Exosome-Specific rRNAmost affected strains) (Hardman et al., 2001). We have
Processing by 5-Fluoruracilsubsequently demonstrated that the exosome is likely
The antiproliferative antimetabolite 5-flourouracil (5FU)to be a major cellular target for 5FU in yeast (see follow-
is one of the most successful and widely used chemo-up section on 5FU).
therapeutics for the treatment of solid tumors in cancerA number of compounds with previously unknown
patients. It is thought that the major cytotoxic effects ofyeast targets induced fitness defects in specific hetero-
5FU occur at the level of DNA synthesis as a competitivezygotes (Figure 4B). Among these findings was the dis-
inhibitor of thymidylate synthetase (Parker and Cheng,covery that molsidomine blocked sterol biosynthesis at
1990). However, a growing body of evidence suggestsa particular step in the pathway (ERG7). In addition,
that the antiproliferation effects of 5FU may result fromwe found that tricyclic antidepressants and tamoxifen
inhibition of RNA metabolism (Longley et al., 2003). Theaffected NEO1, a P-type ATPase with a number of hu-
most convincing argument for the role of RNA metabo-man homologs. Caffeine was found to inhibit the TOR
lism as a target of 5FU comes from experiments showingprotein kinase complex. Other processes such as sphin-
that cotreatment of cells with uridine, but not thymidine,golipid synthesis, fatty acid synthesis, cell wall metabo-
relieves the cytotoxic and apoptotic effects of the druglism, and heme biosynthesis also appear to be targeted
(Engelbrecht et al., 1984; Linke et al., 1996; Pritchard etby compounds in this study. The results from treatment
al., 1997).with 5FU and molsidomine were chosen for follow-up
studies, which are described in the following sections. Treatment of the heterozygous deletion pool with 5FU
Discovering Drug Activities in Yeast
131
Figure 5. Inhibition of Lanosterol Synthase by Molsidomine
(A) Chemical structures and the relationships between molsidomine and its metabolites, SIN-1, SIN-1A, and SIN-1C. Molsidomine is metabolized
in vivo by a series of transformations as illustrated. The vasodilatory properties of molsidomine occur through SIN-1C.
(B) Fitness profile of molsidomine. The top four outliers are labeled in this dot plot. The ERG7 heterozygote displayed the most significant
growth defect in response to molsidomine treatment (P value  1  1016).
(C) Yeast overexpression of ERG7 confers resistance to molsidomine. A wild-type yeast strain was transformed with plasmids pDW394 (circle)
or pDW394-ERG7 (square). Overnight cultures were diluted and grown in the presence of molsidomine (0–10 mg/mL) for 15 hr. The relative
growth for each strain was calculated by dividing the optical density of the drug-treated culture by that of the untreated control. Each condition
was carried out in triplicate.
(D) Inhibition of purified rat liver oxidosqualene cyclase (OSC) activity. The in vitro conversion of [14C] 2,3-oxidosqualene by purified OSC was
measured after incubation at 37C for 30 min with purified OSC. The conversions were analyzed by radio-TLC. The percent activity was
calculated by dividing each value from the drug treatment by that of the untreated control.
(E) Inhibition of recombinant bacterial squalene:hopene cyclase (SHC) activity. The in vitro conversion of [14C]-squalene by recombinant SHC
was measured after incubation at 30C for 30 min. The conversions were analyzed by radio-TLC. The percent activity was calculated by
dividing each value from the drug treatment by that of the untreated control.
revealed drug-induced haploinsufficiency for eight (Venema and Tollervey, 1999). We monitored the re-
moval of internal transcribed spacers, ITS1 and ITS2,genes that play roles in ribosome biogenesis in addition
to the previously reported target CDC21 (Figure 6A). by Northern blot analysis using ITS-specific oligonucleo-
tide probes (Figure 6C). We found that 5FU treatmentFour of the seven genes (RRP6, RRP41, RRP44, and
RRP46) encode components of the exosome, a con- causes the accumulation of an rRNA processing product
we refer to as A2-C2 (Figure 6C). In addition, 5FU treat-served complex required for 5.8S rRNA and snoRNA 3
end processing (Butler, 2002; Mitchell and Tollervey, ment causes a transient increase in 35S pre-rRNA levels
similar to the effects of depletion of individual exosome2000). The other four genes, NOP4, MAK21, SSF1, and
YPR143W, play roles in either 25S rRNA processing, 60S components, including Rrp6p, Rrp41p, and Rrp44p (All-
mang et al., 2000). Interestingly, the untreated rrp6	ribosome production, 27S rRNA processing, or associ-
ate with other nucleolar components (Edskes et al., strain displays a phenocopy of the 5FU-induced accu-
mulation of the A2-C2 rRNA processing product (Fig-1998; Fatica et al., 2002; Ho et al., 2002; Sun and Wool-
ford, 1994). ure 6C).
Next, we asked whether 5FU treatment enhanced theTo further characterize the effect of 5FU, we moni-
tored rRNA intermediates in normal and mutant yeast accumulation of A2-C2 in specific heterozygous deletion
strains identified in this study. The wild-type control andstrains following drug treatment. Figure 6B outlines the
major events in rRNA processing, which begins with each of the heterozygotes were grown in the presence
of 5FU followed by Northern blot analysis to measuresynthesis of the 35S pre-rRNA by RNA polymerase I
and proceeds by a series of endo- and exonucleolytic A2-C2 levels (Figure 6D). Strains that were heterozygous
for components of the exosome (RRP6, RRP41, RRP44,cleavages that yield three of the four mature rRNAs
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Figure 6. Disruption of Exosome Specific rRNA Processing by 5FU
(A) Fitness Profile of 5FU. Eight of the top ten outliers (RRP6, RRP41, MAK21, YPR143W, RRP46, SSF1, RRP44, NOP4) play roles in ribosome
biogenesis. CDC21, the reported target of 5FU, is also among the top ten outliers.
(B) Diagram of the major events of rRNA processing in S. cerevisiae. The positions complementary to oligonucleotide probes used are indicated
below the 35S pre-rRNA. Processing begins with cleavage of the 35S precursor rRNA (35S pre-rRNA) at sites A0 and A1 in the 5 external
transcribed spacer (5 ETS) and at B2 to yield the 32S pre-rRNA. Next, cleavage of 32S pre-rRNA yields 27S pre-rRNA and 20S pre-rRNA,
which is converted to mature 18S rRNA by further cleavage. The 27S pre-rRNA follows either of two parallel pathways each of which yields
mature 25S rRNA. The pathways differ in the mechanism that generates the mature 5 end of 5.8S rRNA. The exosome and Rrp6p form the
3 end of 5.8S rRNA by exonucleolytic removal of the 3 end of 7S pre-rRNA: the exosome removes all but the last 30 nucleotides, which is
then trimmed off by Rrp6p.
(C) Northern blot analysis of rRNA processing intermediates. A wild-type diploid was treated in culture with 200 M 5FU and RNA was prepared
from samples taken at the times indicated at the top of the figure (lanes 1–3). RNA was also prepared from an untreated wild-type haploid
(lane 4) and an isogenic rrp6::KAN mutant (lane 5). The blot was probed with radiolabeled oligonucleotides (indicted at the left of each image)
complementary to specific pre-rRNA intermediates and mature 5.8S rRNA. Notation to the right of each image indicates the identity of the
major pre-rRNA intermediates.
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and RRP46) produced 2- to 10-fold more A2-C2 than the Another advantage of the fitness assay is that biologi-
cal processes that are affected by a given compoundwild-type strain treated with 5FU (Figure 6D). Although
there is evidence that 5FU may result in general RNA are identified in addition to the precise protein target(s).
For example, treatment of the heterozygous deletiondamage, our results reveal a specific molecular mecha-
nism by which 5FU may inhibit cell growth through per- pool with 5FU resulted in the identification of a group
of genes that encode components of the exosome com-turbation of rRNA processing by the exosome complex.
In fact, preliminary data suggest that 5FU prolongs the plex. Another example involved the drug tunicamycin,
which is known to affect protein glycosylation. Besidestime yeast cells spend in G2/M and that this effect
is exacerbated by the exosome mutations (data not identifying the known target (ALG7p), heterozygotes in-
volved in either the endoplasmic reticulum (ER) stressshown).
response (HAC1) or cell wall glycosylation (GFA1) also
displayed sensitivity to tunicamycin. Finally, identifica-Discussion
tion of the fol2/FOL2 strain in response to the sulfa-
based drugs or the cdc21/CDC21 and rho1/RHO1Use of Fitness Profiling For Understanding
Drug Activities strains following staurosporine treatment also confirms
the effectiveness of this assay in detecting affectedWe have demonstrated that fitness profiling is a power-
ful approach for analyzing the modes of action of clini- pathways.
The dataset presented here has yet to be fully minedcally relevant compounds. Identifying the protein targets
of existing drugs can reveal sources of pharmacologi- and offers opportunities for many follow-up experi-
ments. Of the 56 compounds yielding clear outliers, wecally desirable side effects in addition to the mecha-
nisms for unwanted toxicities. Understanding the mo- chose two examples for in-depth characterization by
conventional experimental techniques. In the first exam-lecular mechanisms for therapeutic compounds is also
critical because it allows researchers to develop sec- ple, fitness results suggesting that lanosterol synthase
(Erg7p) may be a target of molsidomine were confirmedond-generation compounds with improved pharmaco-
logical properties. Knowing the cellular targets for clini- in yeast by overexpression resistance and biochemical
analyses of pathway intermediates. This work was fur-cally proven small molecules can also reveal drug
targets that are already validated in humans. ther validated by monitoring the inhibitory activity of this
compound on the bacterial and mammalian enzymesThis highly parallel and sensitive yeast assay offers
several key advantages over traditional approaches for in vitro. Interestingly, the cholesterol-lowering effect of
molsidomine appears to be distinct from the nitric oxideanalyzing drug activities. First, this approach requires
no prior knowledge of compound mode of action, which releasing activity, which accounts for the drug’s vasodi-
latory properties. This new information provides poten-allows truly novel drug activities to be uncovered in a
systematic and unbiased fashion. For example, we tial clinical validation for lanosterol synthase as a safe
and effective target for the development of new choles-found that the tricyclic antidepressants (amitriptyline,
imipramine, desipramine, clomipramine, chlorproma- terol-lowering drugs.
In the second example, we performed a set of experi-zine, and trifluoperazine) affected the growth of the
NEO1 heterozygote (Figure 3C). NEO1 encodes an inte- ments to confirm the hypothesis that 5FU blocks rRNA
processing by the exosome, which may account forgral membrane protein in the P-type ATPase superfamily
(Axelsen and Palmgren, 1998). Although the primary some of this drug’s antiproliferation activities. At present
it remains unclear how inhibition of the exosome bymode of antidepressive action of these compounds oc-
curs by the nonselective inhibition of neurotransmitter 5FU inhibits cellular growth. Defects in rRNA processing
could potentially cause inhibition of protein synthesis.reuptake, these compounds confer a number of deleteri-
ous side effects by mechanisms that are poorly under- Alternatively, recent evidence suggests that tumor sup-
pressor proteins such as nucleolar ARF may mediatestood (Hardman et al., 2001). Evidence for TCA inhibition
of ATPase activity has been documented in human crosstalk between the rRNA processing pathway and
components that regulate cell cycle progression (Ita-erythrocyte plasma membranes and skeletal sarcoplas-
mic reticulum membranes (Plenge-Tellechea et al., hana et al., 2003; Ruggero and Pandolfi, 2003). Our pre-
liminary data (not shown) also suggest that 5FU affects1999; Soler et al., 2000). We found that the growth rate
of the NEO1 heterozygote was also impeded by tamoxi- cell cycle timing in yeast that is exacerbated by muta-
tions in exosome components. Hence, these findingsfen, a potent antiestrogen drug for the treatment of
breast cancer. The chemical structures of the tricyclics are significant in light of a growing body of research
indicating a critical relationship between ribosome bio-and tamoxifen interestingly share a common lipophilic
moiety characterized by an amine tail. Additional studies genesis and cell cycle control (Du and Stillman, 2002;
Ruggero et al., 2003; Sugimoto et al., 2003; Volarevic etwill be needed to further characterize the putative ef-
fects of these compounds on ATPase activity in yeast al., 2000). Moreover, the cytotoxic effects of 5FU in hu-
man cells may result from p53-mediated effects on RNAand humans.
(D) Analysis of A2-C2 rRNA processing product accumulation in wild-type (/) and mutant yeast strains treated for 30 min with the indicated
concentration of 5FU. The top image is a Northern blot probed with OSB155 (see Figure 6B) and the central image shows the same blot
probed with an oligonucleotide complementary to SCR1 RNA (OSB151). The graph illustrates the level of A2-C2 rRNA processing product
determined by storage phosphorimager analysis and normalized to the level of SCR1 for each strain and is the average of two independent exper-
iments.
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metabolism. This is supported by data showing that that this gene encodes a potential target for this drug.
However, the open reading frame of YML176C overlapsadministration of the drug causes apoptosis in p53/,
with ERG1 (YML175C), the known target of terbinafine,but not in p53/ intestinal epithelial cells. In addition,
which suggests that the sensitivity of this heterozygotecoadministration of 5FU with uridine, but not thymidine,
was likely due to the inadvertent disruption of the ERG1inhibited 5FU-induced apoptosis (Pritchard et al., 1997).
open reading frame. Similarly, background mutationsThe dependence of 5FU action on p53 and connections
that are unlinked to the heterozygous locus or crosshy-between p53 and rRNA metabolism suggest that the
bridizing tags may also result in false positives. Thep53 pathway may act as a sensor of defects in rRNA
number of false positives can be minimized by confirm-processing thereby signaling cell cycle arrest and/or
ing the fitness results with the individual deletion strainsapoptosis. A clear understanding of the role of the exo-
and testing whether overexpression of the candidatesome in the p53 response to 5FU may provide a new
gene confers resistance to the drug of interest.opportunity for therapeutic intervention in the treatment
A critical component of this study was the use of aof cancer.
strain-specific error model to identify drug-dependent
effects that are statistically significant. Since some het-Limitations and Technical Considerations
erozygotes have nonspecific growth defects, it is neces-While the fitness assay is a powerful approach for identi-
sary to understand the normal behavior of each strainfying drug targets, there are also a number of limitations.
before calculating drug-induced effects. We determinedFirst, the compound of interest must be able to affect
that a reference set must be populated with a minimumthe growth rate of the cell. Failure of a compound to
of 50 experiments and that chemical treatments areimpart a fitness defect may indicate that (1) the drug
more effective compared to nontreated controls for thetarget is not encoded in the yeast genome; (2) drug
reference set. When performed as described here, thiseffects are masked by other proteins with redundant
method will detect as little as 5–10% growth deficitsactivities; (3) the drug was not correctly metabolized; or
in individual strains (data not shown). However, it is(4) the drug was not able to enter the cell. However, the
important to note that each study must generate its ownability of a compound to affect the growth rate of yeast
reference set due to the inherent variability of experi-does not guarantee that a target will be identified by
mental conditions. Sensitivity could theoretically be in-this approach. In order for this approach to work, a
creased by extending the pool outgrowth beyond 20heterozygote for the target gene must be present in the
generations and by increasing the number of experi-mutant pool. Unfortunately, heterozygotes representing
ments included in the reference set. We have also foundonly about half of the yeast genome were available at
that P values from this approach provide an effective
the time of this study, which resulted in a lower detection
way to rank order the strains in a given drug treatment
rate than would be expected from a full genome pool.
to identify the significant outliers. The ability to compare
Failure to detect the precise protein targets of stauro-
P values across compounds is limited by the fact that
sporine (PKC1) and the sulfa-based drugs (FOL1 and
compounds have very diverse modes of action and the
FOL3) can be attributed to the fact that the target strains
doses of different compounds cannot be considered
were not in the pool. Another requirement of this assay equivalent.
is that the activity level of the targeted protein must be
influenced by the dosage level of the corresponding Future Directions
gene under the conditions profiled. Finally, compounds We have demonstrated that fitness profiling is a power-
that exert their effects through direct interaction with ful approach for studying the activities of clinically rele-
nonprotein elements in the cell, such as DNA (actinomy- vant compounds in yeast. Tagged heterozygous dele-
cin D) or ergosterol (amphotericin B), do not appear tion strains have been made available for virtually every
suitable for this approach. gene in the yeast genome since this study was com-
In some cases, the increased drug sensitivities of het- pleted. This resource coupled with commercially avail-
erozygotes are caused by indirect effects on the cell able tag arrays make it possible to extend this type of
and do not represent primary drug targets. For instance, analysis to the full genome level. In addition, a similar
members of the multidrug resistant (MDR) family of strategy using pools of homozygous deletion strains
transporters (e.g., PDR5) were implicated in a number could be used to reveal targets that are currently masked
of drug treatments. These nonessential efflux pumps by redundant activities. Growth conditions can also be
act to reduce the effective intracellular concentration of modified to assess drug sensitivities of genes that are
certain structural classes of compounds. Deletion of one expressed only under certain physiological conditions.
of the two copies of these genes in a diploid cell can Recently developed techniques to introduce specific
result in a reduced capacity to export drugs from the mutations into all strains of a deletion pool make it possi-
cell, thereby causing a hypersensitivity phenotype of the ble to identify drug effects in a variety of different genetic
heterozygotes. Comparison of gene expression profiles backgrounds (Ooi et al., 2001). Finally, fitness profiling
from putative target deletion strains with those of drug results can be combined with data from other large-
treatments can help distinguish actual drug targets from scale functional genomics efforts to enhance our under-
proteins involved in an indirect cellular drug response standing of compound activities.
(Hughes et al., 2000).
Experimental ProceduresSome of the candidate targets identified with this ap-
proach are due to artifacts that were introduced during
Supplemental Data
the construction of the deletion strains. For example, A comprehensive list of P values for all experiments discussed here
the heterozygote for YML176C displayed increased sen- is available on the Cell website. Log ratio data is available upon re-
quest.sitivity to terbinafine (P value 
 1  1016) indicating
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Yeast Strains and Plasmids rays consisting of either 5873 UP tag probes or 5873 DOWN tag
probes. DNA microarrays consisting of 20-mer probes (see strainIsogenic heterozygous deletion strains were obtained from the Sac-
charomyces Genome Deletion Consortium (Winzeler et al., 1999). A information for probe sequences) were synthesized as described in
Hughes et al. (2000). Hybridizations were done in 3.5 ml of 1 SSTEplasmid expressing yeast ERG7 was constructed by PCR amplifica-
tion of the open reading frame from yeast genomic DNA. The ORF hybridization buffer (1 M NaCl, 10 mM Tris [pH 7.0], 0.5% Triton
X-100) containing 10 pM gridline DNA for 3 hr at 40C. Arrays werewas cloned by in vivo recombination into pDW394, a high copy
URA3 vector with expression driven by the HOR7 promoter. first washed in 6 SSPE  0.05% Triton-X and then in ice-cold
0.06 SSPE. Slides were then scanned on a GMS 418 scanner
(Genetic Microsystems, Woburn, MA).Construction of Heterozygous Deletion Pool
The collection of 3503 heterozygous deletion strains was obtained
from the Saccharomyces Deletion Consortium (see website for Data Analysis
strain and tag information: http://www-sequence.stanford.edu/ Descriptions of formulas used for array quantitation and P value
group/yeast_deletion_project/Enter_function.html) as saturated glyc- derivation are available on the Cell website.
erol stocks in 96-well plates. Strains were transferred to YEPD agar
plates with a 96-well colony replicator (V & P Scientific, Inc., San
Northern Blot AnalysisDiego, CA) and were grown at 30C for 72 hr. All colony-forming
rRNA processing was analyzed by Northern blot analysis of totalunits were collected with a rubber spatula and combined in a 50 ml
RNA samples as described by Briggs et al. (1998). Transfer mem-conical tube. The cell mixture was washed in 30 ml of YEPD and
branes were hybridized with 5 32P-labeled deoxyribonucleotidesdiluted to 1  1010 cells per mL in YEPD with 15% glycerol. Single
OSB151 (5-gtctagccgcgaggaagg-3); OSB155 (5-tccagttacgaaaatuse 2 ml aliquots were flash-frozen in a dry ice/ethanol bath and
tcttgtttttgacaa-3); OSB154 (5-tcttgcccagtaaaagctctcatgc-3);stored at 80C until use.
OSB158 (5-gttcgcctagacgctctcttc-3); OSB157 (5-ggtgaccaattt
caagtta-3); OSB156 (5-cgctgcgttcttcatcgatgcg-3); or OSB138 (5-
Drug Treatments
tcagagatcttggtgataat-3), which are complementary to SCR1 RNA,
To determine the appropriate drug treatment concentrations, a
ITS1, ITS2, and 5.8S, respectively (Figure 6B). Blots were analyzed
5-fold dilution series of each compound was made in synthetic
by storage phosphorimager analysis.
complete medium with 2% glucose and 2% (w/v) casamino acids
(SCC) for eleven 2 drug concentrations and one vehicle control.
Enzyme Activity AssayA 100 l aliquot of each dose was distributed to a 96-well tissue
Chemicalsculture plate in triplicate. Subsequently, a 2 cell suspension was
(3S)-[24,30]2,3-oxidosqualene was synthesized as described by Baimade by thawing an aliquot of the frozen deletion pool on ice before
et al. (1998). Triton X-100 was purchased from Sigma. Molsidomine,harvesting by centrifugation, washing twice with SCC, and diluting
SIN-1-hydrochloride, and SIN-1A/CD complex (10%, w/w SIN-1Ato 2.65  104 cells/ml in SCC at room temperature. A 100 l aliquot
content) were obtained from Alexis Biochemicals.of the 2 cell mixture was then added to each of the 96 wells in
Biological Materialsthe drug-containing tissue culture plate. Plates were then incubated
Rat liver lanosterol cyclase was purified according to the procedureat 30C with gentle agitation on a rotary shaker for 15 hr reaching
described by Abe and Prestwich (1995).a density of 1.3  107 cells per mL (vehicle control). The pool fitness
Enzyme Assay for OSC(PF) was calculated (PF 
 1  [(log(OD600treated/OD600untreated))/
The reaction mixture contained 100 mM sodium citrate, [pH 7.4],(log(2)g )], where g is the number of generations assumed to be 10)
0.1% (v/v) Triton X-100, 5 M [14C]2,3-oxidosqualene (52.6 mCi/for each drug concentration and doses that resulted in 0.70  PF 
mmol), and 5 g of purified enzyme in a final volume of 1 mL. After0.96 were selected for fitness profiling experiments.
incubation at 37C for 30 min, the reaction was stopped by addition
of 1 ml CH2Cl2. The extract was concentrated using a Speed-Vac,Fitness Profiling
and then subjected to silica gel TLC (Whatmann LK6D). The TLCAn aliquot of the frozen pool was thawed at room temperature and
plates were developed with CH2Cl2. The conversions were then ana-diluted in 100 ml of SCC to a final density of 1.3  107 cells/ml. A
lyzed by radio-TLC (Bio-Scan, System 200 Imaging Scanner). All5 ml aliquot was harvested immediately (G-0) by centrifugation and
assays were carried out in triplicate.frozen at 80C until DNA isolation. Dilutions of 1.3  104 cells/ml
Enzyme Assay for SHC Bacterial Lanosterol Cyclasein 20 ml aliquots were grown at 30C for 10 generations to a density
Recombinant A. acidocaldarius lanosterol cyclase was expressedof 1.3  107 cells/ml. Cultures were then diluted once again to 1.3 
in E. coli and purified as outlined by Ochs et al (1992). To 50 l of104 cells/ml in fresh media or fresh media containing drug. After
5 mM sodium citrate, [pH 6.0], 0.1% (v/v) Triton X-100 was addedanother ten population doublings, 1  108 cells from each culture
4 l of a solution of SHC (600 g/ml) and 3 l (0.021 Ci) of [14C]-were harvested (G-20) as described above. All harvested cell pellets
squalene (1 mM in ethanol, 7 mCi/mmole). After incubation at 60Cwere thawed on ice and subjected to a 30 s, 50 krpm mechanical
for 30 min, the reaction was stopped by addition of 1 ml CH2Cl2. Thelysis with 0.5 mm glass beads in a Mini-Beadbeater (Biospec Prod-
extract was concentrated using a Speed-Vac and then subjected toucts, Bartlesville, OK). Genomic DNA was subsequently isolated
silica gel TLC. The TLC plates were developed to a distance of 5using the MasterPure Yeast DNA Purification Kit (Epicentre
cm in chloroform and after drying for 15 cm in hexane. The conver-#mpy80200), quantified, and normalized to 15 ng/l.
sions were then analyzed by radio-TLC.
Tag Amplification and Hybridization to DNA Microarrays
For each treatment, genomic DNA isolated from cultures harvested Acknowledgments
at G-0 and G-20 culture was labeled with Cy3 and Cy5, respectively.
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gaattcatcg-3) and 5 M of unlabeled DOWN tag reverse primer (5- Genome Database (http://www.yeastgenome.org) for information
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